Plasma uric acid and tumor volume are highly predictive of outcome in nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Lin, Hui ^a   Lin, Huan Xin ^a   Ge, Nan ^b   Wang, Hong Zhi ^a   Sun, Rui ^a   Hu, Wei Han ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Xiangtan Central Hospital   (China)

Author keywords

Intensity modulated radiotherapy; Nasopharyngeal carcinoma; Plasma uric acid; Prognosis; Tumor volume

Indexed keywords

CISPLATIN; PACLITAXEL; URIC ACID;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; PLEURA METASTASIS; RETROSPECTIVE STUDY; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; URIC ACID; YOUNG ADULT;

EID: 84878916108     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-121     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
3. Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ, Zhao C. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer 2011, 117:1874-1883. 10.1002/cncr.25754, 21509764.
4. Xiao WW, Han F, Lu TX, Chen CY, Huang Y, Zhao C. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2009, 74:1070-1076. 10.1016/j.ijrobp.2008.09.008, 19231110.
5. Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, Kwan WH, Leung SF, Zee B, Chan AT. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2004, 60:1440-1450. 10.1016/j.ijrobp.2004.05.022, 15590175.
6. Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 2009, 27:3684-3690. 10.1200/JCO.2008.19.9109, 2720082, 19564532.
7. Crohns M, Saarelainen S, Kankaanranta H, Moilanen E, Alho H, Kellokumpu-Lehtinen P. Local and systemic oxidant/antioxidant status before and during lung cancer radiotherapy. Free Radic Res 2009, 43:646-657. 10.1080/10715760902942824, 2691182, 19444690.
8. Wu Z, Zeng RF, Su Y, Gu MF, Huang SM. Prognostic significance of tumor volume in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy. Head Neck 2013, 35:689-694. 10.1002/hed.23010, 22715047.
9. Butler EB, Teh BS, Grant WH, Uhl BM, Kuppersmith RB, Chiu JK, Donovan DT, Woo SY. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 1999, 45:21-32. 10.1016/S0360-3016(99)00101-7, 10477002.
10. Sak A, Stuschke M, Wurm R, Budach V. Protection of DNA from radiation-induced double-strand breaks: influence of replication and nuclear proteins. International journal of radiation biology 2000, 76:749-756. 10.1080/09553000050028896, 10902728.
11. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, Hastings C, Blaney SM, Relling MV, Reaman GH. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol 2001, 19:697-704.
12. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981, 78:6858-6862. 10.1073/pnas.78.11.6858, 349151, 6947260.
13. Chang CC, Chen MK, Liu MT, Wu HK. The effect of primary tumor volumes in advanced T-staged nasopharyngeal tumors. Head Neck 2002, 24:940-946. 10.1002/hed.10151, 12369073.
14. Shen C, Lu JJ, Gu Y, Zhu G, Hu C, He S. Prognostic impact of primary tumor volume in patients with nasopharyngeal carcinoma treated by definitive radiation therapy. Laryngoscope 2008, 118:1206-1210. 10.1097/MLG.0b013e31816ed587, 18418278.
15. Chen C, Fei Z, Pan J, Bai P, Chen L. Significance of primary tumor volume and T-stage on prognosis in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. Jpn J Clin Oncol 2011, 41:537-542. 10.1093/jjco/hyq242, 21242183.
16. Sze WM, Lee AW, Yau TK, Yeung RM, Lau KY, Leung SK, Hung AW, Lee MC, Chappell R, Chan K. Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control. Int J Radiat Oncol Biol Phys 2004, 59:21-27. 10.1016/j.ijrobp.2003.10.027, 15142631.
17. Chua DT, Sham JS, Kwong DL, Tai KS, Wu PM, Lo M, Yung A, Choy D, Leong L. Volumetric analysis of tumor extent in nasopharyngeal carcinoma and correlation with treatment outcome. Int J Radiat Oncol Biol Phys 1997, 39:711-719. 10.1016/S0360-3016(97)00374-X, 9336154.
18. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012, 13:163-171. 10.1016/S1470-2045(11)70320-5, 22154591.
19. Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Lu TX, Siu L, Tan T, Chan LK, Ng WT. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer 2011, 47:656-666. 10.1016/j.ejca.2010.10.026, 21112774.
20. Gu MF, Liu LZ, He LJ, Yuan WX, Zhang R, Luo GY, Xu GL, Zhang HM, Yan CX, Li JJ. Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma. Int J Cancer 2013, 132:215-223. 10.1002/ijc.27638, 22610788.